Three-dimensional conformal radiotherapy for locoregionally recurrent non-small cell lung cancer after initial radiotherapy.
- Author:
Ying-jie WANG
1
;
Lü-hua WANG
;
Ji-ma LÜ
;
Lu-jun ZHAO
;
Ze-fen XIAO
;
Hong-xing ZHANG
;
Qin-fu FENG
;
Zhong ZHANG
;
Wei-bo YIN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; pathology; radiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lung Neoplasms; pathology; radiotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; radiotherapy; Neoplasm Staging; Radiation Pneumonitis; etiology; Radiotherapy Dosage; Radiotherapy, Conformal; adverse effects; methods; Remission Induction; Survival Rate
- From: Chinese Journal of Oncology 2006;28(3):227-229
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the feasibility, therapeutic effects and normal tissue complications of three-dimensional conformal radiotherapy (3DCRT) for locoregionally recurrent non-small cell lung cancer after initial radiotherapy.
METHODSBetween August 1999 and August 2003, 27 such patients were treated with 3DCRT after initial radiotherapy. This series consisted of 25 men and 2 women with a median age of 64 years. Radiotherapy was delivered at 2 Gy per fraction, 5 fractions per week, to a median dose of 50 Gy. Treatment results and normal tissue complications were assessed with WHO and RTOG/EORTC criteria.
RESULTSBased upon a median follow-up time of 20.6 months, 25 patients (92.6%) completed the planned 3DCRT treatment. Their clinical symptom relief rate was 79.1%, and the response rate was 59.3% with a complete remission rate of 14.8% (4/27), partial remission rate of 44.4% (12/27). The overall 1- and 2-year survival (OS) rates were 73.8% and 25.4% with a median survival time (MST) of 20 months. The 1- and 2-year local progression free survival (LPFS) rates were both 88.8%. Grade 2 and grade 3 acute radiation pneumonitis developed in 7.4% (2/27) and 11.1% (3/27). Grade 2 late radiation pneumonitis developed in 11.1% (3/27).
CONCLUSION3DCRT is feasible and advisable for locoregionally recurrent non-small-cell lung cancer, giving a good immediate tumor response and acceptable normal tissue complications.
